Study highlights anti-inflammatory properties of herbal medicine, Erigeron breviscapus to treat osteoarthritis

FHS
April 4, 2024
9:45 am

Researchers explored using Erigeron breviscapus (EB) as a treatment for osteoarthritis (OA).

Detailed data on Alnylam’s heart drug show substantial benefit, while competition likely awaits

LONDON — An experimental drug from Alnylam Pharmaceuticals substantially cut the risk of death and serious cardiovascular complications among patients with an increasingly diagnosed heart

August 30, 2024

Phase I/II trial begins for SpyGlass intraocular drug delivery implant – Pharmaceutical Technology

SpyGlass Pharma is initiating Phase I/II clinical trials investigating its drug delivery platform in patients with glaucoma and visually significant cataracts. SpyGlass Pharma’s platform consists

October 31, 2023

Is Guillain-Barré syndrome induced by SARS-CoV-2 vaccination?

Researchers investigated whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines induced Guillain-Barré syndrome.

June 19, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.